Trizivir approved in Canada.
D002170:Canada; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D017277:Drug Approval; D004338:Drug Combinations; D016527:Drug Costs; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000099227:Abacavir
D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir